

CERTIFICATE OF MAILING

RECEIVED
DEU 8/8/2003
TECH CENTER 1600/2900

I hereby certify that this paper is being deposited with the U.S. Postal Service as first class mail on the date indicated below in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Name of Person Mailing: CHRIS MYERS

Signature: Chris Myers Date: November 25, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Supplemental Information Disclosure Statement Address to: Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450	First Named Inventor	Chris Allen Broka, et al.
	Application Number	09/925,883
	Filing Date	August 7, 2001
	Group Art Unit	1625
	Examiner	Binta M. Robinson
	Attorney Docket No.	R0072B-REG
	Title	Quinoline Derivatives As Anti-Inflammatory Agents

Sir:

Transmittal Letter for Supplemental Information Disclosure Statement

Transmitted herewith for filing in the above-entitled patent application is an Information Disclosure Statement, in compliance with 37 CFR §1.56, which may be material to the patentability of the subject patent application.

[X] Attached are:

- Fee Transmittal Form with Deposit Account Authorization
- Form 1449, "List of References Cited," with copies of references C1-C11
- Return postcard

[X] The Information Disclosure Statement is being submitted more than three (3) months after the filing date and after the mailing date of the first Office action on the merits, but before a final action under § 1.113 or a notice of allowance under § 1.311. The **\$180.00** fee set forth in §1.17(p) is authorized on the attached Fee Transmittal.

12/04/2003 CNGUYEN 00000032 181700 09925883


01 FC:1806 180.00 DA

Broka, et al.
USSN 09/925,883

Attorney Docket No. R0072B-REG

The Examiner is respectfully requested to consider these documents and to make them of record in the subject application.


Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Grant D. Green', with a stylized flourish at the end.

Grant D. Green
Reg. No. 31,259
Attorney for Applicants

Roche Palo Alto LLC
Patent Law Dept. – M/S A2-250
3431 Hillview Avenue
Palo Alto, CA 94304
November 25, 2003

Direct Phone (650) 855-5311
Fax (650) 855-5322
grant.green@Roche.com



RECEIVED
LIST OF REFERENCE(S) CITED
DEC 08 2003

TECH CENTER 1600/2900

Atty. Docket No.
R0072B-REG

Serial No.
09/925,883

Applicant(s)
Chris Allen Broka, et al.

Filing Date
August 7, 2001

Group
1625


PUBLICATIONS

	C1	ANDERSON, et al., "The Role of Cyclooxygenase Inhibitors in Cancer Prevention," Current Pharmaceutical Design , 2002, pp 1035-1062, Vol. 8
	C2	DeRUITER, et al., "Synthesis and Aldose Reductase Inhibitory Activity of Substituted 2-Oxoquinoline-1-acetic Acid Derivatives," J. Med. Chem. , 1986, pp 2024-2028, Vol. 29
	C3	DING, et al., "Cyclooxygenases and Lipoxygenases as Potential Targets for Treatment of Pancreatic Cancer," Pancreatology , 2001, pp 291-299, Vol. 1
	C4	GASSMAN; et al., "A General Method for the Synthesis of Isatins," J. Org. Chem. , 1977 pp 1344-1348, Vol. 42:8
	C5	HEWAWASAM, et al., "A General Method for the Synthesis of Isatins: Preparation of Regiospecifically Functionalized Isatins from Anilines," Tetrahedron Letters , 1994, pp 7303-7306, Vol. 35:40
	C6	KRAYNACK, et al., "An Improved Procedure for the Regiospecific Synthesis of Electron Deficient 4- and 6-Substituted Isatins," Tetrahedron Letters , 1998, pp 7679-7682, Vol. 39
	C7	OZAWA, et al., "Palladium-Catalyzed Double Carbonylation of Aryl Halides Affording α -Keto Amides: Applications to Synthesis of Isatin and Quinoline Derivatives," J. Org. Chem. , 1986 pp 415-417, Vol. 51
	C8	RAHME, et al., "The Cyclooxygenase-2-Selective Inhibitors Rofecoxib and Celecoxib Prevent Colorectal Neoplasia Occurrence and Recurrence," Gastroenterology , 2003, pp 404-412, Vol. 125
	C9	SANCHEZ-ALCAZA, et al., "Cyclooxygenase (COX) inhibitors induce apoptosis in non-small cell lung cancer through cyclooxygenase independent pathways," Lung Cancer , 2003, pp 33-44, Vol. 40
	C10	SINGH-RANGER, et al., "Current concepts in cyclooxygenase inhibition in breast cancer," J. of Clinical Pharmacy and Therapeutics , 2002, pp 321-327, Vol. 27
	C11	STEELE, et al., "Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer," Mutation Research , 2003, pp 137-144, Vol. 523-524

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**FEE TRANSMITTAL
for FY 2003**

Effective 01/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT (\$)** 180.00

Complete if Known

Application Number	09/925,883
Filing Date	August 7, 2001
First Named Inventor	Chris Allen Broka, et al.
Examiner Name	Binta M. Robinson
Art Unit	1625
Attorney Docket No.	R0072B-REG

RECEIVED

DEC 08 2003

TECH CENTER 1625/2003

METHOD OF PAYMENT (check all that apply)☐ Check ☐ Credit card ☐ Money ☐ Other ☐ None
Order☒ Deposit Account:Deposit
Account
Number

18-1700

Deposit
Account
NameRoche Palo Alto LLC
3431 Hillview Avenue
Palo Alto, CA 94304

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments
☐ Charge any additional fee(s) during the pendency of this application
☐ Charge fee(s) indicated below, except for the filing fee
to the above-identified deposit account.**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	770			Utility filing fee	
1002	330			Design filing fee	
1003	520			Plant filing fee	
1004	750			Reissue filing fee	
1005	160			Provisional filing fee	

SUBTOTAL (1)

(\$0)

2. EXTRA CLAIM FEES

			Extra Claims		Fee from below		Fee Paid	
Total Claims		-20 **	=		X	18	=	
Independent Claims		-3 **	=		X	86	=	
Multiple Dependent					X		=	0

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	18			Claims in excess of 20
1201	86			Independent claims in excess of 3
1203	280			Multiple dependent claim, if not paid
1204	84			** Reissue independent claims over original patent
1205	18			** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2)

(\$0)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)**3. ADDITIONAL FEES**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	410	2252	205	Extension for reply within second month	
1253	930	2253	465	Extension for reply within third month	
1254	1,450	2254	725	Extension for reply within fourth month	
1255	1,970	2255	985	Extension for reply within fifth month	
1401	320	2401	160	Notice of Appeal	
1402	320	2402	160	Filing a brief in support of an appeal	
1403	280	2403	140	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,300	2453	650	Petition to revive - unintentional	
1501	1,300	2501	650	Utility issue fee (or reissue)	
1502	470	2502	235	Design issue fee	
1503	630	2503	315	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17 (q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	180.00
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	750	2809	375	Filing a submission after final rejection (37 CFR § 1.129(a))	
1810	750	2810	375	For each additional invention to be examined (37 CFR § 1.129(b))	
1801	750	2801	375	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3)

(\$180.00)

SUBMITTED BY

Complete (if applicable)

Name (Print/Type)	Grant D. Green	Registration No.	31,259	Telephone	650/ 855-5311
Signature		Date	November 25, 2003		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Docs #122925